A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Trial Profile

A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; EMD 640744 (Primary) ; Epacadostat (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immunovaccine
  • Most Recent Events

    • 07 Dec 2017 As per MR, in cohort 1, 10 patients are enrolled. While in cohort 2, 16 to 40 patients will be enrolled. So, kept planned patients as 50 (highest patient No.)
    • 05 Dec 2017 According to an Immunovaccine media release, planned number of patients changed from 40 to 50.
    • 05 Dec 2017 According to an Immunovaccine media release, results from the first cohort of the study (n=10) is announced. Dosing the patients for second cohort is ongoing and expect the results in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top